Raymond James Financial’s ADMA Biologics ADMA Stock Holding History
Bought
Maintained
Sold
Other funds holding ADMA
Raymond James Financial's ADMA Position: Q3 2026 in Review
Raymond James Financial reduced its ADMA Biologics (ADMA) stake by 7.5% in Q3 2026, selling an estimated $256K and leaving 339,443 shares worth $3.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3095.
Raymond James Financial first reported a position in ADMA in Q4 2024 and has held it in 8 quarters since. The position peaked at $27.7M in Q2 2025. 329 funds tracked by Wall St. Rank hold ADMA as of Q3 2026.
- Raymond James Financial held 339,443 shares of ADMA Biologics worth $3.4M as of Q3 2026.
- Raymond James Financial sold 27,671 ADMA Biologics shares in Q3 2026, an estimated $256K.
- ADMA Biologics made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #3095 holding.
- Raymond James Financial first reported a position in ADMA Biologics in Q4 2024 and has held it in 8 quarters since.
- Raymond James Financial's ADMA Biologics position peaked at $27.7M in Q2 2025.
- 329 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2026.
Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.